Altogether, these data indicate that biglycan acts as a molecular regulator with dual and context-dependent functions in BC: while its stromal and endothelial expression promotes angiogenesis, immune evasion, and metastatic relapse, its absence appears to restrain tumour progression. The gene discussed is BGN; the disease is breast cancer.